Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischaemic stroke or TIA.
OBJECTIVE
Young patients with an ischaemic stroke or transient ischaemic attack (TIA) often have no vascular risk factors. Hyper-homocysteinaemia is an established risk factor for stroke in elderly patients but it is uncertain whether it is also important for the prognosis of young ischaemic stroke and TIA patients. We examined the possible effect of the plasma homocysteine level on the risk of recurrent vascular events in patients between 18 and 45 years of age.


METHODS
The study population consisted of 161 consecutive patients with a recent cerebral infarction or TIA. Data on the primary event and the homocysteine level were collected retrospectively from hospital records. General practitioners and patients were contacted by telephone to record vascular events and the type of medication used during the follow-up period. Vascular events included cerebral infarction, TIA, pulmonary embolism, venous thrombosis, myocardial infarction and peripheral arterial disease.


RESULTS
A Kaplan- Meier curve showed a dose effect relationship between event-free survival time and tertiles of the homocysteine level (Log rank statistic 5.91; p=0.05). The Cox hazard ratio, after adjustment for homocysteine lowering treatment, was 1.7 (95 % CI, 1.1 to 2.8) for any vascular outcome event, 1.9 (95% CI, 1.1 to 3.0) for arterial outcome events and 1.8 (95 % CI, 1.1 to 2.9) for cerebral outcome events.


CONCLUSIONS
In spite of our small number of outcome events we found a significant association at the 95% confidence level between homocysteine level and the risk of recurrent vascular events in young patients with an ischaemic stroke or TIA. The association is of the same magnitude as in elderly people.
Bos
Michiel J
MJ
Dept. of Neurology, Erasmus MC, 1738, 3000 DR, Rotterdam, The Netherlands. d.dippel@erasmusmc.nl
van Goor
Mary-Lou P J
ML
Koudstaal
Peter J
PJ
Dippel
Diederik W J
DW
D000293:Adolescent; D000328:Adult; D002544:Cerebral Infarction / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006711:Homocystine / Q000097:blood*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000097:blood* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D020521:Stroke / Q000097:blood* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000097:blood* / Q000628:therapy
D006711:Homocystine
JAMA. 2004 Feb 4;291(5):565-75
14762035
Stroke. 1993 Jan;24(1):35-41
7678184
JAMA. 1995 Oct 4;274(13):1049-57
7563456
Arch Intern Med. 1999 Jan 11;159(1):38-44
9892328
Lancet. 2000 Feb 12;355(9203):517-22
10683000
Arch Neurol. 1995 May;52(5):491-5
7733844
Ann Neurol. 2002 Mar;51(3):285-9
11891822
Lancet. 1995 Nov 25;346(8987):1395-8
7475822
Cerebrovasc Dis. 2001 Aug;12(2):91-8
11490102
Stroke. 1983 Jan-Feb;14(1):110-4
6337424
N Engl J Med. 1998 Apr 9;338(15):1042-50
9535670
Stroke. 2002 Aug;33(8):1956-62
12154245